BPH 治疗市场-全球行业规模、份额、趋势、竞争、机会、预测，2018-2028 年药物治疗、手术治疗、最终用户、地区分析

全球良性前列腺增生 (BPH) 治疗市场预计在 2024-2028 年预测期内将出现显着增长，原因是男性老年人口的增加以及与良性前列腺增生相关的泌尿系统疾病的增加。 根据全球癌症观察站的数据，2020 年全球大约报告了 19,292,789 例新癌症病例，其中前列腺癌最常见，报告了 14,14,259 例癌症病例。 此外，公众缺乏对前列腺早期诊断和检测的认识，预计将进一步推动 BPH 治疗市场的增长。

产品发布提振市场

手术是比药物治疗更好的选择，但由于手术割伤和烧伤会对身体造成术后伤害，患者往往会选择药物治疗。 然而，微创手术的发展正在改变患者的态度，并为手术器械製造商带来竞争优势。 例如，Teleflex 于 2020 年 8 月推出了 Urolift，这是一种改进的用于治疗 BPH 的组织控制系统。 可以在系统中放置一个小植入物，将前列腺小叶保持在缩回位置以打开尿道。 具有挑战性前列腺解剖结构的患者，例如大的侧叶和阻塞性中叶，是该设备的目标人群。 这些产品的推出有望推动市场增长。

研发成长

开髮用于治疗前列腺癌等各种危及生命的疾病的新药和手术的需求不断增长，导致研发方法和活动的快速进步，从而导致市场增长。我们支持增长。 Clinicaltrials.gov 显示，全球有 17 项处于不同发展阶段的临床试验用于治疗良性前列腺增生症 (BPH)。 这凸显了世界范围内为开发良性前列腺增生 (BPH) 药物而进行的大量研究和开发，从而支持了市场的增长。 然而，2017 年 2 月，为了开展癌症联合研究活动，成立了综合肿瘤学中心 (CIO)。

医疗保健投资增加

由于先进的手术非常昂贵，因此癌症治疗由政府资助。 Ayushman公司成立

Bharat Health and Wellness Centers (AB-HWC) 于 2018 年 2 月获得印度政府批准，用于诊断和筛查三种常见癌症，即口腔癌、乳腺癌和宫颈癌。宣布。 2018 年发起的另一项举措，即 Pradhan Mantri Jan Arogya Yojana，已根据其规范将癌症治疗设施增加到一定的支出。 根据该计划，化疗和放疗套餐以及外科肿瘤学作为内嵌医院癌症护理的一部分被涵盖，总共有 435 种癌症护理程序被定义为增加。

可自定义

根据市场数据，TechSci Research 根据公司的具体需求提供定制服务。 该报告可以定制为：

公司信息

• 对其他市场参与者（最多 5 家公司）进行深入分析和概况分析

内容

第 1 章概述

• 市场定义
• 市场范围
  • 目标市场
  • 研究目标年份
  • 主要市场细分

第二章研究方法论

• 调查目的
• 基线调查方法
• 主要行业合作伙伴
• 主要协会和次要信息
• 调查方法
• 数据三角测量和验证
• 假设和限制

第 3 章执行摘要

• 市场概览
• 主要市场细分概述
• 主要市场参与者概览
• 主要地区/国家概览
• 市场驱动因素、挑战和趋势

第 4 章 VOC（客户之声）

第 5 章 BPH 设备的全球市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 通过药物治疗（α-受体阻滞剂、5-α-还原□抑製剂、磷酸二酯□-5 抑製剂）
  • 通过手术方法（经尿道前列腺切除术 (TURP)、前列腺尿道提升术 (PUL)、前列腺切除术、激光手术、经尿道微波疗法 (TUMT)、经尿道前列腺针切除术 (TUNA)），其他（Rezum 疗法） , Urolift 疗法, 其他)
  • 最终用户（医院/诊所、门诊手术中心、其他）
  • 按地区（北美、欧洲、亚太地区、南美、中东/非洲）
  • 按公司分类（2022 年）
• 市场地图
  • 通过药物
  • 手术治疗除外
  • 最终用户
  • 按地区

第 6 章北美 BPH 设备市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 通过药物
  • 手术治疗除外
  • 最终用户
  • 按国家
• 北美：国家/地区分析
  • 美国
  • 加拿大
  • 墨西哥

第 7 章：欧洲 BPH 药物市场前景

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 通过药物
  • 手术治疗除外
  • 最终用户
  • 按国家
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 意大利
  • 西班牙

第8章亚太地区BPH药物市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 通过药物
  • 手术治疗除外
  • 最终用户
  • 按国家
• 亚太地区：国家/地区分析
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳大利亚

第 9 章南美 BPH 治疗市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 通过药物
  • 手术治疗除外
  • 最终用户
  • 按国家
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲 BPH 药物市场前景

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 通过药物
  • 手术治疗除外
  • 最终用户
  • 按国家
• MEA：国家分析
  • 阿联酋 BPH 治疗
  • 沙特阿拉伯的 BPH 治疗
  • 南非 BPH 治疗
  • Turkiye BPH 治疗
  • 埃及 BPH 治疗

第 11 章市场动态

• 司机
  • 良性前列腺增生的患病率增加
  • 老年人口增加
  • 技术进步
• 做
  • 昂贵的程序
  • 与技术相关的副作用
  • 缺乏进行侵入性手术的熟练专业人员

第12章市场趋势与发展

• 新药开发
• 新手术的开发

第13章临床试验分析

• 正在进行的临床试验
• 已完成临床试验
• 已完成临床试验
• 管道细分（按开发阶段）
• 管道细分（按状态
• 管道细分（按研究类型）
• 按地区划分的渠道细分
• 临床试验热图

第14章竞争格局

• 业务概览
• 提供的产品
• 近期发展状况
• 财务状况（针对上市公司）
• 主要人员
  • Boston Scientific Corporation
  • Coloplast Corporation
  • Teleflex Incorporated
  • Olympus Corporation
  • Glaxo Smith Kline PLC
  • Eli Lily
  • Abott Laboratories
  • Medifocus Inc.
  • Urologix, LLC
  • Pfizer Inc

第 15 章战略建议

第十六章关于研究公司/免责声明

Global Benign Prostate Hyperplasia (BPH) Treatment Market is anticipated to observe impressive growth during the forecast period, 2024-2028, owing prevalence of benign prostatic hyperplasia rising global male geriatric population, rise in urological disorders associated with BPH. According to Global Cancer Observatory, in 2020, around 19,292,789 new cancer cases were reported worldwide, among which Prostate Cancer was the most prevalent type of cancer, accounting for 14,14,259 cases 2020. Additionally, the lack of awareness among the public for early prostate diagnosis and detection is further expected to drive the growth of the Benign Prostate Hyperplasia (BPH) Treatment Market.

The growing prevalence of fatal diseases has significantly increased the demand for different types of drugs and surgeries. Additionally, expansion in research & development activities being initiated by various governments, ambulatory surgical centers, and pharmaceutical companies across the globe is further expected to create opportunities for the growth of the Benign Prostate Hyperplasia (BPH) Treatment market in the coming years. According to Statista Research Department, as of now, the United States will be the leading country worldwide in terms of spending on research and development, with expenditure exceeding around USD679.4 billion.

According to the Cancer fact sheet, the cancer rates are highest in Australia/New Zealand and North America. Prostate cancer is the fourth most common cancer overall and the second most common cancer in men.

Product Launches Boost Market

Surgery is a superior alternative to treating BPH with medicine; however, due to the post-operative harm that surgical cuts and burns do to the body, patients tend to choose medication. Patients' perceptions have changed as a result of the development of minimally invasive techniques and surgical equipment makers now have a competitive advantage. For instance, Teleflex Inc. launched the UroLift improved tissue control system in August 2020 to treat BPH. To open the urethra, small implants that keep the prostate lobes in their retracted posture might be placed into the system. Patients with challenging prostatic anatomy, such as those who have large lateral lobes or an obstructive median lobe, are the target population for the device. These product launches are anticipated to boost the growth of the market.

Growth in Research & Development

Rapid advancements in research and development (R&D) practices and activities are propelling the growth of the market on account of the growing need for developing novel drug/surgery for the treatment of different life-threatening diseases like prostate cancer. According to Clinicaltrials.gov, 17 clinical trials are in different phases of development across the globe for Benign Prostate Hyperplasia (BPH) Treatment. This clearly indicates that a lot of R&D is being done across the globe for developing Benign Prostate Hyperplasia (BPH) Treatment., thereby supporting the growth of the market. However, in February 2017, The Centre for Integrative Oncology (CIO) was established as a joint venture of the All India Institute of Ayurveda (AIIA) and the National Institute of Cancer Prevention and Research (NICPR-ICMR) with the intention of collaborative research activities in cancer.

Rising Investment in Healthcare

Advanced surgical therapies are very expensive; therefore, financial assistance is provided by the government for cancer treatment. An establishment of Ayushman

Bharat Health and Wellness Centers (AB-HWCs) were announced by the Government of India in February 2018 for the diagnosis and screening of three common cancers, i.e., oral, breast, and cervical. Another initiative launched in 2018, namely Pradhan Mantri Jan Arogya Yojana, surged treatment facilities for cancer up to a certain expenditure as per their norms. The chemotherapy and radiotherapy packages, along with surgical oncology, are covered as part of cancer treatment in the impaneled hospitals under the scheme, and a total of 435 procedures have been defined for the treatment of cancer.

Market Segmentation

The Global Benign Prostate Hyperplasia (BPH) Treatment Market can be segmented based on drug treatment, surgical treatment, end user, region, and competitional landscape. Based on drug treatment, the market can be categorized into alpha-blockers, 5-alpha reductase inhibitors, and Phosphodiesterase-5 Inhibitors. Based on surgical treatment, the market can be fragmented into transurethral resection of the prostate (TURP), prostatic urethral lift (PUL), Prostatectomy, laser surgery, transurethral microwave Technique (TUMT), transurethral needle ablation of the prostate (TUNA), and others. Based on end users, the market can be grouped into hospitals and clinics, ambulatory surgical centers, and others.

Company Profiles

Boston Scientific Corporation, Coloplast Corporation, Teleflex Incorporated, Olympus Corporation, Glaxo Smith Kline PLC, Eli Lily, Abbott Laboratories, Medifocus Inc., Urologix, LLC, and Pfizer Inc. are some of the key players operating in the Global Benign Prostate Hyperplasia (BPH) Treatment market.

Report Scope

In this report, Global Benign Prostate Hyperplasia (BPH) Treatment Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Benign Prostate Hyperplasia (BPH) Treatment Market, By Drug Treatment:

• Alpha Blockers
• 5-Alpha Reductase Inhibitors
• Phosphodiesterase-5 inhibitors

Benign Prostate Hyperplasia (BPH) Treatment Market, By Surgical Treatment:

• Transurethral resection of the prostate (TURP)
• Prostatic Urethral Lift (PUL)
• Prostatectomy
• Laser surgery
• Transurethral microwave Technique (TUMT)
• Transurethral needle ablation of the prostate (TUNA)
• Others

Benign Prostate Hyperplasia (BPH) Treatment Market, By End User:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Benign Prostate Hyperplasia (BPH) Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Turkey
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Benign Prostate Hyperplasia (BPH) Treatment market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global BPH Devices Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Treatment (Alpha Blockers, 5-Alpha Reductase Inhibitors, and Phosphodiesterase-5 Inhibitors)
  • 5.2.2. By Surgical Treatment (Transurethral resection of the prostate (TURP), Prostatic Urethral Lift (PUL), Prostatectomy, laser surgery, Transurethral microwave Technique (TUMT), Transurethral needle ablation of the prostate (TUNA), and others (Rezum therapy, Urolift therapy, etc)
  • 5.2.3. By End User (hospitals and clinics, ambulatory surgical centres, and Others)
  • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.5. By Company (2022)
• 5.3. Market Map
  • 5.3.1. By Drug Treatment
  • 5.3.2. By Surgical Treatment
  • 5.3.3. By End User
  • 5.3.4. By Region

6. North America BPH Devices Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Treatment
  • 6.2.2. By Surgical Treatment
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States BPH Devices Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Treatment
      • 6.3.1.2.2. By Surgical Treatment
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada BPH Devices Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Treatment
      • 6.3.2.2.2. By Surgical Treatment
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico BPH Devices Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Treatment
      • 6.3.3.2.2. By Surgical Treatment
      • 6.3.3.2.3. By End User

7. Europe BPH Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Treatment
  • 7.2.2. By Surgical Treatment
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France BPH Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Treatment
      • 7.3.1.2.2. By Surgical Treatment
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany BPH Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Treatment
      • 7.3.2.2.2. By Surgical Treatment
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom BPH Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Treatment
      • 7.3.3.2.2. By Surgical Treatment
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy BPH Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Treatment
      • 7.3.4.2.2. By Surgical Treatment
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain BPH Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Treatment
      • 7.3.5.2.2. By Surgical Treatment
      • 7.3.5.2.3. By End User

8. Asia-Pacific BPH Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Treatment
  • 8.2.2. By Surgical Treatment
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China BPH Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Treatment
      • 8.3.1.2.2. By Surgical Treatment
      • 8.3.1.2.3. By End User
  • 8.3.2. Japan BPH Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Treatment
      • 8.3.2.2.2. By Surgical Treatment
      • 8.3.2.2.3. By End User
  • 8.3.3. India BPH Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Treatment
      • 8.3.3.2.2. By Surgical Treatment
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea BPH Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Treatment
      • 8.3.4.2.2. By Surgical Treatment
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia BPH Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Treatment
      • 8.3.5.2.2. By Surgical Treatment
      • 8.3.5.2.3. By End User

9. South America BPH Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Treatment
  • 9.2.2. By Surgical Treatment
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil BPH Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Treatment
      • 9.3.1.2.2. By Surgical Treatment
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina BPH Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Treatment
      • 9.3.2.2.2. By Surgical Treatment
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia BPH Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Treatment
      • 9.3.3.2.2. By Surgical Treatment
      • 9.3.3.2.3. By End User

10. Middle East and Africa BPH Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Treatment
  • 10.2.2. By Surgical Treatment
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE BPH Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Treatment
      • 10.3.1.2.2. By Surgical Treatment
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia BPH Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Treatment
      • 10.3.2.2.2. By Surgical Treatment
      • 10.3.2.2.3. By End User
  • 10.3.3. South Africa BPH Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Treatment
      • 10.3.3.2.2. By Surgical Treatment
      • 10.3.3.2.3. By End User
  • 10.3.4. Turkey BPH Treatment Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Drug Treatment
      • 10.3.4.2.2. By Surgical Treatment
      • 10.3.4.2.3. By End User
  • 10.3.5. Egypt BPH Treatment Market Outlook
    • 10.3.5.1. Market Size & Forecast
      • 10.3.5.1.1. By Value
    • 10.3.5.2. Market Share & Forecast
      • 10.3.5.2.1. By Drug Treatment
      • 10.3.5.2.2. By Surgical Treatment
      • 10.3.5.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
  • 11.1.1. Increasing prevalence of Benign Prostate Hyperplasia
  • 11.1.2. Growing geriatric population
  • 11.1.3. Technological Advancement
• 11.2. Challenges
  • 11.2.1. High Cost of Procedure
  • 11.2.2. Side effects associated with the technique
  • 11.2.3. Lack of Skilled Professionals to conduct invasive surgeries

12. Market Trends & Developments

• 12.1. Development of new drugs
• 12.2. Development of new surgeries

13. Clinical Trial Analysis

• 13.1. Ongoing Clinical Trials
• 13.2. Completed Clinical Trials
• 13.3. Terminated Clinical Trials
• 13.4. Breakdown of Pipeline, By Development Phase
• 13.5. Breakdown of Pipeline, By Status
• 13.6. Breakdown of Pipeline, By Study Type
• 13.7. Breakdown of Pipeline, By Region
• 13.8. Clinical Trials Heat Map

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Product Offerings
• 14.3. Recent Developments
• 14.4. Financials (In Case of Listed Companies)
• 14.5. Key Personnel
  • 14.5.1. Boston Scientific Corporation
  • 14.5.2. Coloplast Corporation
  • 14.5.3. Teleflex Incorporated
  • 14.5.4. Olympus Corporation
  • 14.5.5. Glaxo Smith Kline PLC
  • 14.5.6. Eli Lily
  • 14.5.7. Abott Laboratories
  • 14.5.8. Medifocus Inc.
  • 14.5.9. Urologix, LLC
  • 14.5.10. Pfizer Inc

15. Strategic Recommendations

16. About Us and Disclaimer